Shashikant Bhandari wins second prize for Best Research Publication Award
PUNE: While over 10 million people living with HIV are awaiting treatment, the scientists are still in the quest for an effective treatment regimen for AIDS and the key targets that can be explored to stop growth of causative organism HIV.
Against this backdrop, pharmaceutical researcher Shashikant Bhandari is doing research on Reverse Transcriptase (RT) and HIV Integrese enzymes as a target for the control of growth of the HIV virus in human body.
Bhandari, the head of the department of pharmaceutical chemistry at AISSMS College of Pharmacy, won the second prize for the Best Research Publication Award, instituted by Computer Aided Drug, Molecule Designing software company Vlife Sciences Pvt Ltd.
The co-authors of the scientific paper were Kailash Bothara, Vidya Pawar, Deepak Lokwani, A R Madgulkar, Debashis Mitra and Sudeep Sabde.
The title of his research paper is 'Design of Potential Reverse Transcriptase Inhibitors Containing Isatin Nucleus Using Molecular Modeling Studies'. Earlier, the paper was published at a conference held at Sweden.
The most promising compounds selected from molecular modeling studies will be subjected to further screenings of the drug discovery phases and the molecules showing promising results will be protected by filing patent application, Bhandari said.
ART THERAPY HELPING LAKHS OF PATIENTS
In 2009 alone, 1.2 million people received HIV anti-retroviral therapy (ART) for the first time - an increase in the number of people receiving treatment of 30 per cent in a single year. Expanding access to the treatment has contributed to a 19 per cent decline in deaths among people living with HIV between 2004 and 2009. Yet, there are many who do not have access to treatment, says UNAIDS report 2009-2010.
Join Sakaal Times on Facebook: